Biotechnology Industry | Healthcare Sector | Mr. Paul A. Romness M.P.H. CEO | AMEX Exchange | - ISIN |
United States Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
OS Therapies Incorporated stands as a clinical stage biopharmaceutical company committed to the advancement of treatments for osteosarcoma and other solid tumors. The company is actively engaged in the identification, development, and commercialization phases of novel treatments. With its foundation laid in 2018 and headquartered in Rockville, Maryland, OS Therapies Incorporated has made significant strides towards offering innovative solutions in the fight against cancer.
An off-the-shelf immunotherapy candidate developed by OS Therapies Incorporated, OST-HER2 represents a pivotal development in the landscape of cancer treatment. Designed to harness the body's immune system to fight cancer, this product exemplifies the company's commitment to innovative cancer treatment paradigms.
A next-generation tunable antibody-drug conjugate (ADC), OST-TDC features a state-of-the-art plug-and-play platform with tunable pH-sensitive silicone linkers. This technology allows for the precise targeting and delivery of cancer therapeutics, showcasing OS Therapies Incorporated's forefront position in advancing ADC technologies for cancer treatment.